Healthcare (SH:603313) EBSCN·2025-05-11 10:15Investment Rating - The report maintains a "Buy" rating for the company, indicating a favorable outlook for investment returns over the next 6-12 months [5]. Core Views - The company plans to repurchase shares for employee stock ownership plans, signaling confidence in long-term development [1][2]. - The U.S. mattress manufacturing is experiencing a trend of returning production to domestic markets due to anti-dumping tariffs and trade policies, which is expected to continue [2][3]. - The company is expected to benefit from improved operational efficiency in its U.S. production bases and the ongoing development of its online business and retail channels, leading to enhanced profit contributions from the North American market [3]. - The report forecasts a profit turnaround, with projected net profits for 2025-2027 being 307 million, 464 million, and 573 million yuan respectively, alongside corresponding EPS of 0.54, 0.81, and 1.00 yuan [3][10]. Summary by Sections Share Repurchase - The company intends to repurchase shares worth between 0.85 to 1.7 billion yuan at a maximum price of 10.90 yuan per share, which will account for 1.37% to 2.73% of the total share capital [1][2]. Market Trends - The U.S. has implemented multiple rounds of anti-dumping tariffs on mattresses from various countries, including China, which has led to a significant decrease in mattress imports, with a year-on-year decline of 12.7% and 9.6% expected for 2023 and 2024 respectively [2]. Financial Projections - The report projects revenue growth from 7.976 billion yuan in 2023 to 12.725 billion yuan in 2027, with a compound annual growth rate of approximately 14.33% [10]. - The company’s net profit is expected to recover from a loss of 151 million yuan in 2024 to a profit of 307 million yuan in 2025, reflecting a significant turnaround [10]. Profitability Metrics - The report anticipates an improvement in profitability, with the gross margin expected to stabilize around 38.4% by 2027, and a projected return on equity (ROE) of 11.87% in the same year [12].